✦ LIBER ✦
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
✍ Scribed by Trarbach, T; Moehler, M; Heinemann, V; Köhne, C-H; Przyborek, M; Schulz, C; Sneller, V; Gallant, G; Kanzler, S
- Book ID
- 110000310
- Publisher
- Nature Publishing Group
- Year
- 2010
- Tongue
- English
- Weight
- 318 KB
- Volume
- 102
- Category
- Article
- ISSN
- 0007-0920
No coin nor oath required. For personal study only.